Domain Names E-CommerceLitigationIP Rights MaintenanceIP as PropertyNews & BulletinsTrademarksIntroductionBiotechnologyComputer Related InventionsUS and Foreign Patent PracticePatents
HomeAbout UsContact UsSearchQuick Search:
 
Patents / Biotechnology / US Biotechnology Practice
 

4.2 The Written Description Requirement


Claims that are broader than the supporting disclosure may be held to be invalid. Thus if the claim excludes a feature that the description indicates is essential such a claim may be invalid, particularly if the inventor admits that he only thought of omitting the feature from the claim after seeing the products of competitors. [34]

In general problems can arise as to whether this requirement was met when the applicant amends the claims during prosecution of the application. In view of the Federal Circuit’s view that the purpose of this requirement is to determine whether or not the inventor had possession of the invention at the time of filing the application, issues can arise, especially in the area of biotechnology or other areas of technology where there is a low degree of predictability, even with the original claims, notwithstanding the fact that the original claims themselves are deemed to be part of the original disclosure. [35] In such a case, in order to comply with this requirement, it is necessary that "the disclosure of the application relied upon reasonably conveys to the artisan that the inventor had possession at [the time of filing] of the later claimed subject matter". [36] In 1997, in University of California v. Eli Lilly and Co. [37] the Court of Appeals for the Federal Circuit affirmed a lower court decision that a patent which included claims directed to mammalian, vertebrate and human cDNA was invalid because there was no written description of the cDNA. The Federal Circuit noted that a written description of DNA "requires a precise definition, such as by structure, formula, chemical name or physical properties". The Court stated that describing a method for preparing cDNA or describing the protein coded for by the cDNA while describing how to make and use the cDNA did not meet the written description requirement. A prior decision in Fiers v. Sugamo [38] held that:

"An adequate description of DNA requires more than a mere statement that it is part of the invention and reference to a potential method of isolating it; what is required is a description of the DNA itself".

The moral to be drawn from these cases is that when drafting one's application one should try to ensure that basis has been provided for as many different ways of claiming the invention as possible, for example by providing bases for claiming subgeneric groupings and sub combinations of integers so that if one ever needs to fall back to claims for such limited views of the invention one can point to a specific written description of them in the original text.



[34] The Gentry Gallery Inc. v. The Berkline Corp., 45 USPQ2d 1498. This case has given rise to much comment and has been referred to as creating a "missing element rule" which has apparently led to some district courts giving very restricted interpretations to patents holding valid only those that claim the preferred embodiments. It seems clear, however, that this was not what the Federal Circuit intended. In Johnson Worldwide Associates Inc. v. Zebco Corp, 50 USPQ2d 1607, the Court distinguished Gentry, pointing out that in that case the specification had given a particular location of an element as being "the only possible location" and stating that in Gentry "the patent's disclosure makes crystal clear that a particular (i.e. narrow) understanding of a claim term is an essential element of the inventor's invention”. The issue was also considered by the Northern District of California in Reiffin v. Microsoft Corp, 59 USPQ2d 1421, which deduced, from a concurring opinion of Judge Newman in a prior consideration of other aspects of the case by the Federal Circuit (54 USPQ2d 1915), that there was no such thing as an omitted element rule.
[35] In re Koller, 613 F.2d 819 204 USPQ 702 (CCPA 1980); In re Smith, 481 F.2d 910, 178 USPQ 629 (CCPA 1973).
[36] Wang Labs Inc. v. Toshiba Corp., 993 F.2d 858, 26 USPQ2d 1767.
[37] 43 USPQ2d 1398.
[38] 25 USPQ2d 1601 (Fed. Cir. 1993).


Previous Next Contents
Contact Us


[Home] [About Ladas & Parry LLP] [Contact Us] [Search]
[Trademarks] [Domain Names & E-Commerce] [Patents & Copyrights]
[Litigation] [IP Rights Maintenance] [IP as Property] [News & Bulletins]

© Copyright 2002 John Richards - Posted July 2002
Please read our disclaimer.